Introduction {#Sec1}
============

The tetramisole enantiomer levamisole is used as a veterinary anthelminthic that was also approved as an adjuvant in colon cancer treatment in some countries before it was withdrawn from the market in 2000 because of its adverse side effects^[@CR1]^. In 2004, the U.S. Drug Enforcement Agency (DEA) initially detected levamisole as a adulterant in cocaine seizures^[@CR2]^. In the mobile drug-checking program of Switzerland, levamisole was recognized in 2008 for the first time as an adulterant in street cocaine. Measurements revealed that between 2009 and 2016, 50 to 70% of all cocaine specimens contained levamisole (Fig. [1](#Fig1){ref-type="fig"}). Similar trends of extensive levamisole contamination of street cocaine across the last decade were shown for the US and for different European countries^[@CR3],[@CR4]^. The recent drop of the levamisole prevalence in Switzerland is a phenomenon that to our knowledge has not been shown in other countries so far (Fig. [1](#Fig1){ref-type="fig"}). By contrast, in October 2017, the DEA reported that 87% of the seized and analyzed cocaine bricks contained levamisole.^[@CR4]^ Thus, levamisole is currently the most common cocaine adulterant in Europe and North America^[@CR3],[@CR4]^.Fig. 1Additives in cocaine samples in Switzerland between 2004 and 2018.Lines indicate percent frequency of occurrence. Recruitment periods of cocaine users for both studies are shaded in gray. The data were collected in mobile laboratories in Berne, Zurich, and Basel (total *n* = 771). Data were provided by the Office of the Cantonal Pharmacist, Health & Social Welfare Department State of Berne, Switzerland (Daniel Allemann, Hans-Jörg Helmlin, and André Mürner). \*Data only from the first half-year 2018 (January--August)

The mixture of cocaine with other pharmacological components (primarily prescription drugs and over-the-counter agents, see Fig. [1](#Fig1){ref-type="fig"}) prior to being sold on the streets lead to a decline of cocaine purity in the main consumer markets of North America and Europe^[@CR5]^. These adulterants were generally added for two reasons. First, they are available, cheap, have similar chemo-physical properties (color, texture, melting point) and, thus, increase the profit of the drug dealer. Second, some additives are supposed to enhance the psychoactive effects of the drug by exerting additional pharmacological effects^[@CR1],[@CR6]^. In the case of levamisole, it was shown that the compound itself has negligible effects on monoamine transporters, but it was proposed that the mother compound is metabolized---among others---to aminorex, a psychostimulant agent that shows potent amphetamine-like effects^[@CR1],[@CR6],[@CR7]^. A drug discrimination study with rats showed very recently that levamisole in fact potentiates the subjective effects of cocaine when administered concomitantly^[@CR8]^.

Levamisole has a wide range of adverse side effects. In recent years, an accumulating body of literature described a clear linkage between levamisole-adulterated cocaine use and the occurrence of neutropenia and agranulocytosis, vasculitis, retiform purpura and other forms of skin necrosis, vasculopathy, arthralgia, and leukoencephalopathy^[@CR1],[@CR9]--[@CR11]^. Its potential neurotoxicity was first reported in dogs experimentally exposed to levamisole showing disseminated perivascular cuffing with mononuclear cells throughout the brain^[@CR12]^. Since 1992, a number of case reports suggested that the association between the administration of levamisole (in cancer therapy or through cocaine intake) and multifocal inflammatory leukoencephalopathy is also apparent in humans^[@CR1],[@CR9],[@CR13]^. In sum and although exact data on the prevalence of toxicity related to levamisole-adulterated cocaine abuse are missing so far^[@CR3]^, its wide distribution and potential neurotoxicity have been classified a serious public health concern worldwide^[@CR11],[@CR14]^. Although it is important to better understand the specific neuropsychiatric risks associated with levamisole exposure^[@CR1]^ no case--control study investigating the neuropsychiatric risks of levamisole-contaminated cocaine has been published yet.

Previously, we have shown that the intensity of cocaine intake covaries with cognitive impairments in cocaine users (CU), suggesting that the well-described cognitive deficits in this population are largely drug-induced but also potentially reversible^[@CR15]--[@CR17]^. In this context, we now hypothesize that cocaine-related cognitive impairments might not only derive from cocaine itself, but also from its main adulterant levamisole. Thus, in Study 1, we compared two CU groups with similar cocaine use severity but with high (highLevCU) vs. low recent levamisole exposure (lowLevCU) and a matched stimulant-naive control group in their performance in a comprehensive neuropsychological test battery. Low vs. high levamisole exposure was categorized according to a levamisole--cocaine ratio (LCR) in hair samples of the participants. Both compounds were measured by cutting-edge quantitative hair analyses. In line with the above mentioned literature of cocaine-induced cognitive dysfunctions and levamisole-induced neurotoxic effects, we hypothesized that higher levamisole exposure is associated with more severe cognitive dysfunctions.

Based on the findings from Study 1, showing significantly worse executive functions in highLevCU compared to lowLevCU, we subsequently performed a second study with structural magnetic resonance imaging (MRI) in a subsample with similar group classification criteria. In Study 2, we focused on regions-of-interest (ROI) in the frontal lobe---which have been consistently linked to executive function measures used in Study 1^[@CR18]-[@CR21]^ as well as on an occipital control region in order to examine whether these levamisole-related cognitive dysfunctions are specifically associated to structural alterations of the frontal cortex. Accordingly, we expected that high levamisole exposure is linked to cortical thinning explicitly in the frontal lobe.

Materials and Methods {#Sec2}
=====================

Participants {#Sec3}
------------

### Study 1 {#Sec4}

The present data were collected as part of the Zurich Cocaine Cognition Study (ZuCo^2^St). The study included 75 CU, 78 healthy and stimulant-naive healthy controls (for recruitment and selection details see Methods [S1](#MOESM1){ref-type="media"}). The three groups were matched for age, verbal intelligence, sex, and smoking status. The sample of Study 1 shows a 91% overlap with a sample that was previously published^[@CR15]^. Exclusion criteria for all participants were an acute or previous neurological disorder or head injury, any clinically significant medical disease, and use of prescription drugs affecting the brain. Additional specific exclusion criteria for both CU groups were the use of opioids, polysubstance use, and any Axis I DSM-IV adult psychiatric disorder---with the exception of cocaine, cannabis, and alcohol abuse; a history of affective disorders (acute major depression was excluded); and attention-deficit hyperactivity disorder (ADHD). Specific exclusion criteria for the control subjects were any current or former Axis I DSM-IV psychiatric disorder and any form of addiction or regular illegal drug use (lifetime \> 15 occasions), with the exception of recreational cannabis use. Inclusion criteria for the two user groups were cocaine as primary used illegal drug, cocaine use of \>0.5 g per month, and an abstinence duration of \<6 months. Before the testing session, participants were asked to abstain from illegal substances for at least 72 h and not to consume alcohol for 24 h. Compliance with these instructions was controlled by urine drug screenings (Methods [S2](#MOESM1){ref-type="media"}). All participants in both studies provided written informed consent and were compensated for their participation. Both studies were approved by the Cantonal Ethics Committee of Zurich.

### Study 2 {#Sec5}

A total of 29 CU and 38 healthy cocaine-naive controls were included in Study 2. A subsample of 17 individuals previously participated in Study 1 (8 controls, 9 CU; for details see Methods [S3](#MOESM1){ref-type="media"}). Exclusion and inclusion criteria for CU and healthy controls were largely identical to Study 1, apart from that psychiatric medication was allowed in CU in Study 2. Moreover, six participants with alcohol dependence (three in each CU group) and two highLevCU with opioid co-use were included for power reasons. However, the inclusion of these participants did not affect the main results (Tables [S1](#MOESM1){ref-type="media"}/[S2](#MOESM1){ref-type="media"}). Participants were mostly right-handed (92.5%) and there was no group difference in handedness (*χ*^2^(2) = 3.85, *p* = 0.15).

Group classification {#Sec6}
--------------------

When available, 6 cm hair samples were cut from the occiput enabling to objectively estimate drug use and levamisole exposure during the last 6 months. Hair samples were analyzed with liquid chromatography-tandem mass spectrometry (Methods [S2](#MOESM1){ref-type="media"}). As in Study 1 only 2 of 75 CU (2.7%) and in Study 2 only 1 of 29 CU (3.4%) did not display any traces of levamisole in hair, we decided to compare low vs. high exposure groups. The decisive criterion for the group assignment was a LCR (levamisole concentration/cocaine concentration) higher/lower than 25%. The LCR-cutoff of 25% was equal to the mode value in the right-skewed LCR distribution curve (Figure [S1](#MOESM1){ref-type="media"}).

### Study 1 {#Sec7}

CU were split into 26 CU with a LCR of \<25% (low levamisole exposure CU, lowLevCU) and 49 CU with a LCR of \>25% (high levamisole exposure CU, highLevCU). For 28 of the 75 CU, \<6 cm were available so that at least 3 cm samples were analyzed (3-month drug exposure).

### Study 2 {#Sec8}

CU were assigned to either the lowLevCU (*n* = 12) or the highLevCU (*n* = 17) group, respectively. For 10 out of 29 CU, only 3 cm hair samples were available.

Procedure {#Sec9}
---------

Trained psychologists conducted the Structured Clinical Interview (SCID-I) according to DSM-IV^[@CR22]^. Drug use was assessed with the Interview for Psychotropic Drug Consumption and ADHD symptoms by means of the ADHD self-rating scale (ADHD-SR)^[@CR23],[@CR24]^ The verbal IQ was estimated by a standard German vocabulary test^[@CR25]^.

Neuropsychological test battery (Study 1) {#Sec10}
-----------------------------------------

The test battery consisted of the Letter Number Sequencing Task (LNST)^[@CR26]^ a German version of the Rey Auditory Verbal Learning Test (RAVLT)^[@CR27]^ and four tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB, <http://www.cantab.com>): Rapid Visual Processing (RVP), Spatial Working Memory (SWM), Intra/Extradimensional Set-Shifting (IED), and Paired Associates Learning (PAL). Analogous to our previous work^[@CR15],[@CR28]^, 15 predefined cognitive test parameters were *z*-transformed on the basis of means and standard deviations of the control group (*n* = 78) and---in respect of data reduction---combined into four cognitive domains (attention, working memory, declarative memory, and executive function). These four domains were further equally integrated into a global cognitive index (GCI)^[@CR15],[@CR28]^.

Structural MRI acquisition and image processing (Study 2) {#Sec11}
---------------------------------------------------------

All subjects were scanned using a 3T Philips Achieva whole-body scanner equipped with a 32-channel receive head coil. High-resolution structural scans were collected using a standard T1-weighted 3D magnetization-prepared rapid gradient echo (MPRAGE) pulse sequence with repetition time (TR) = 8.08 ms, echo time (TE) = 3.7, field of view (FOV) = 240×240 mm, 160 slices, voxel size of (1×1×1)mm^3^. Cortical surface reconstruction was performed using the software package FreeSurfer v5.3.0 (<http://surfer.nmr.mgh.harvard.edu/>, Methods [S4](#MOESM1){ref-type="media"})^[@CR29]--[@CR31]^. ROIs were extracted by parcelating the cortex using the Desikan--Killiany Atlas^[@CR32]^. Based on the findings from Study 1, we restricted our analysis to ROIs in the lateral frontal lobes. Next to the mean cortical thickness over the whole cortical surface, our analysis included the middle frontal gyrus (MFG, caudal and rostral MFG), inferior frontal gyrus (IFG, pars opercularis, pars orbitalis, pars triangularis), and the lateral orbitofrontal gyrus (lOFG). We also included the superior frontal gyrus (SFG), a region associated with executive functions^[@CR33]^. The pericalcarine cortex (primary visual cortex) was used as a control region due to its low concentration of dopamine transporters^[@CR34],[@CR35]^ and low involvement in executive functions (Figure [S2](#MOESM1){ref-type="media"}). As we did not expect lateralized effects of a systemic drug application, extracted thickness values for each cortical area were averaged across hemispheres. This procedure was additionally justified as cortical thickness in all ROIs was significantly correlated between the right and left hemisphere (Methods [S5](#MOESM1){ref-type="media"}). Thickness measures within the ROIs were z-transformed on the basis of means and standard deviations of the control group (*n* = 38) for better comparisons between the ROIs.

Statistical analysis {#Sec12}
--------------------

Demographic and drug use data were analyzed with Pearson's *χ*^2^ tests, Students *t* tests, and analyses of variance (ANOVA), where appropriate. Group differences analyses in cognitive performance and cortical thickness were conducted by analyses of covariance (ANCOVA), followed by Sidak-corrected post hoc comparisons. In accordance with our previous study^[@CR15]^, age and verbal IQ were introduced as covariates. Because ADHD has been linked to cognitive functioning in CU^[@CR15],[@CR28]^, and to alterations in brain structure^[@CR36],[@CR37]^, all ANCOVAs were additionally adjusted for the ADHD-SR score^[@CR24]^. Given that lowLevCU and highLevCU 1) paid similar average prices for 1 g cocaine (Table [1](#Tab1){ref-type="table"}, Table [S3](#MOESM1){ref-type="media"}) and 2) reported comparable socioeconomic background in both studies (Table [S4](#MOESM1){ref-type="media"}), socioeconomic status was not considered as a covariate. In the ANCOVAs that focused on the cocaine group comparison (lowLevCU vs. highLevCU), we introduced two further covariates: abstinence duration (as lowLevCU and highLevCU differed in self-reported days since last use, see Table [1](#Tab1){ref-type="table"}) and cumulative cocaine dose because of the increased risk of cognitive impairment by ascending lifetime use of cocaine^[@CR15]^. An additional cortical thickness analysis including duration of cocaine intake was calculated to control for differences between the two CU groups in Study 2 (Table [S3](#MOESM1){ref-type="media"}). For correlation analyses the drug use parameters were log-transformed because they deviated from the normal distribution (Shapiro--Wilk *W* \< 0.001). All confirmatory statistical comparisons were carried out on a significance level of *p* \< 0.05.Table 1Demographic data and drug use pattern Study 1Controls (*n* = 78)LowLevCU (*n* = 26)HighLevCU (*n* = 49)Value^a^df, df~err~*p*Age (y)30.2 (8.9)33.0 (9.5)31.5 (9.1)*F* = 1.032.1500.36Sex (f/m)23/557/1911/38*x*^2^ = 0.7620.68Verbal IQ (MWT-B)^b^105.4 (9.2)101.4 (8.7)102.2 (10.7)*F* = 2.502.1500.09Education (y)10.7 (1.7)9.8 (1.3)\*9.8 (1.7)\*\**F* = 6.182.150**0.003**Smoking (y/n)^c^57/2123/339/10*x*^2^ = 2.8120.25BDI score^d^4.4 (4.4)8.4 (6.1)\*9.6 (8.2)\*\*\**F* = 12.252.150 **\<** **0**.**001**ADHD-SR score^e^7.6 (4.7)11.2 (6.3)15.9 (9.1)\*\*\*°*F* = 23.782.150 **\<** **0.001**CocaineTimes per week^g^---2.0 (2.2)1.8 (1.9)*T* = 0.50730.62g per week^g^---3.8 (6.2)3.3 (6.4)*T* = 0.34730.74Years of use---7.7 (6.8)8.6 (5.4)*T* = −0.63730.53 Maximum dose (g/day)---6.5 (6.7)5.8 (6.2)*T* = 0.48730.63Cumulative dose (g)---4130 (8272)2658 (6689)*T* = 0.83730.41Last consumption (days)^h^---29.4 (37.0)13.3 (15.9)*T* = 2.1273**0.04**Urine toxicology (neg/pos)^i^78/021/533/16*x*^2^ = 1.5210.22Average price paid for 1 g (CHF)^j^ 1 g (CHF)^j^---97.5 (19.6)87.5 (21.5)*T* = 1.95730.06Hair analysisCocaine pg/mg---10,261 (20,667)12,993 (24,031)*T* = −0.49730.62Benzoylecgonine pg/mg---2853 (6901)2550 (4365)*T* = 0.23730.82Norcocaine pg/mg---292 (655)312 (484)*T* = −0.15730.88Levamisole pg/mg---967 (1745)6931 (11,737)*T* = −3.4873**0.001**Levamisole--cocaine ratio---0.12 (0.1)0.64 (0.3)*T* = −10.0773**\<0.001**AlcoholPure ethanol g per week^g^109.6 (121.9)185.2 (281)192.2 (204.5)\**F* = 3.612.150**0.03**Years of use12.6 (9.0)11.7 (7.9)13.3 (7.2)*F* = 0.342.1500.71NicotineCigarettes per day^g^8.8 (9.6)16.7 (13.1)\*\*13.5 (10.3)\**F* = 6.682.150**0.002**Years of use8.4 (8.7)13.6 (9.6)\*12.9 (8.5)\**F* = 5.572.150**0.005**Cannabisg per week^g^0.4 (0.9)1.5 (4.0)0.7 (1.7)*F* = 2.812.1500.06Years of use4.3 (5.7)7.4 (9.2)9.6 (7.7)\*\*\**F* = 8.612.150**\<0.001**Cumulative dose (g)665 (3182)3289 (7433)\*1823 (2886)*F* = 4.182.150**0.02**Last consumption (days)^h^41 (57);*n* *=* 3431 (43);n = 1425 (31);n = 34*F* = 1.082.790.34Urine toxicology (neg/pos)^i^68/1018/835/14*x*^2^ = 6.352**0.04**Amphetamineg per week^g^0.0 (0.0)0.0 (0.1)0.1 (0.2)\**F* = 4.152.150**0.02**Years of use0.0 (0.0)1.1 (3.1)1.5 (2.9)\*\*\**F* = 8.232.150**\<0.001**Cumulative dose (g)0.0 (0.1)6 (23.7)28.4 (66.8)\*\*\**F* = 8.142.150**\<0.001**Last consumption (days)^h^122 (0)\
*n* = 197 (71)\
*n* = 559 (54)\
*n* = 16*F* = 1.232.190.31Hair analysis pg/mg1 (7)24 (69)118 (313)\*\**F* = 6.572.150**0.002**MDMATablets per week^g^0.0 (0.0)0.0 (0.0)0.1 (0.2)\*\*\*°*F* = 7.932.150**\<0.001**Years of use0.3 (1.7)1.3 (2.4)3 (4.5)\*\*\**F* = 11.832.150**\<0.001**Cumulative dose (tablets)0.9 (3.2)69.9 (154.3)\*54.1 (168.4)\**F* = 5.212.150**0.007**Last consumption (days)^h^5 (0)\
*n* = 192 (0)\
*n* = 171 (87)\
*n* = 17*F* = 0.312.160.741Hair analysis pg/mg4 (23)177 (337)831 (1902)\*\*\*°*F* = 8.952.150**\<0.001**HallucinogensCumulative dose (times)0.7 (1.8)9.7 (22.2)\*\*6.8 (10.5)\*\**F* = 8.762.150**\<0.001**Means and standard deviations. Significant *p* values are shown in bold^a^ANOVA (all groups; significant Sidak post hoc test vs. control group: \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; vs. lowLevCU: °*p* \< 0.05; °°*p* \< 0.01); *x*² test (all groups/cocaine users only) for frequency data; Independent t-test (cocaine users only)^b^Verbal IQ was assessed by the Mehrfachwahl--Wortschatz--Intelligenztest^[@CR25]c^Smoking habits were assessed by the Fagerstroem Test of Nicotine Dependence^[@CR63]d^*BDI* Beck Depression Inventory^[@CR64]e^*ADHD-SR* ADHD self-rating scale^[@CR24]f^Craving for cocaine was assessed by the Brief-CCQ^[@CR65]g^Average use during the last 6 months^h^Last consumption is averaged only for persons who used the drug in the last 6 months. In this case, sample size (*n*) is shown^i^Cut-off values for cocaine = 150 ng/ml and for Tetrahydrocannabinol 50 ng/ml^[@CR66]j^Price for 1 g cocaine in Swiss Francs paid by cocaine users (self-report). The quoted price is presumably below the real street price as some users paid reduced rates at intermediaries. Moreover, individuals who got the cocaine for free (e.g., as a gift) were excluded (*n* = 1 lowLevCU and *n* = 1 highLevCU)

Results {#Sec13}
=======

Study 1 {#Sec14}
-------

### Demographic characteristics and drug use {#Sec15}

As intended by the matching procedure, the three groups did not differ regarding age, verbal IQ, sex distribution, and smoking status (Table [1](#Tab1){ref-type="table"}). Additionally, there were no differences regarding the average price paid for 1 g of cocaine (Table [1](#Tab1){ref-type="table"}) and socioeconomic status between both groups (Table [S4](#MOESM1){ref-type="media"}). However, both CU groups had significantly fewer years of education and higher BDI scores than controls but did not differ from each other. Moreover, highLevCU displayed significantly higher ADHD-SR scores than lowLevCU. As a consequence of the group classification, the two CU groups differed strongly in their absolute levamisole concentrations and levamisole-related LCR but displayed similar values in any other cocaine-related hair toxicology or self-reported cocaine use parameter (with exception of abstinence duration). Additionally, hair samples and cumulative doses revealed a clear dominance of cocaine compared with other illegal drugs, as intended by the inclusion and exclusion criteria.

### Neurocognitive measures {#Sec16}

As shown before in this sample^[@CR15]^, controls and CU (lowLevCU + highLevCU) differed significantly in the GCI and all four domains (F(1148) = 10.64--28.34, *p* ≤ 0.001) (Table [S5](#MOESM1){ref-type="media"}). Three-group ANCOVAs (controls vs. lowLevCU vs. highLevCU) for the GCI (F(2147) = 15.26, *p* \< 0.001) and across all four cognitive domains (F(2147) = 6.70--10.45, *p* = 0.002--0.0001) showed significant group effects (Fig. [2a](#Fig2){ref-type="fig"}, Table [S6](#MOESM1){ref-type="media"}). Linear trends across groups were shown for all comparisons (*p* \< 0.01--0.001), suggesting not only a cocaine but also a levamisole effect on cognitive functioning. The post hoc pairwise comparisons showed that lowLevCU differed from controls in the GCI, attention, and working memory domain, while highLevCU differed from controls in all cognitive domains (Fig. [2a](#Fig2){ref-type="fig"}). In general, effect sizes were considerably higher for highLevCU (*d* = 0.57--0.80) compared to lowLevCU (*d* = 0.32--0.59). Subsequently, to adjust for even subtle differences in cocaine use intensity, both CU groups were compared using ANCOVAs in which abstinence duration und cumulative lifetime dose of cocaine were additionally included. Here, highLevCU showed a stronger impairment of executive functions with a medium effect size compared to lowLevCU (*F*(1,68) = 5.02, *p* \< 0.05, *d* = 0.55). Additionally, the GCI (*F*(1,68) = 3.21, *p* = 0.08, 0.42) and declarative memory (*F*(1,68) = 3.21, *p* = 0.08, *d* = 0.44) showed statistical trends towards significance with approximately medium effect sizes (Fig. [2b](#Fig2){ref-type="fig"}). The impact on executive function was mainly driven by a worse performance in the IDE task and recall consistency (Table [S7](#MOESM1){ref-type="media"}), indicating more pronounced impairments specifically in rule acquisition and reversal learning as well as in memory organization in highLevCU. An exploratory analysis of the IDE stages revealed that highLevCU made more errors specifically in the intradimensional set-shifting (pre-ED errors: (*F*(1,68) = 0.01, *p* \< 0.05, *d* = 0.64) but not in the extradimensional set-shifting (ED errors: *F*(1,68) = 6.02, *p* = 0.94, *d* = 0.02; Figure [S3](#MOESM1){ref-type="media"}). Notably, in a combined CU group, the executive function performance correlated negatively with the log-transformed levamisole values in hair samples (*r* = −0.23, *p* \< 0.05, one-tailed; Figure [S4](#MOESM1){ref-type="media"}).Fig. 2Mean z-scores and standard errors for the global cognitive index (GCI) and the four cognitive domains.**a** All values corrected for age, verbal IQ, and ADHD (based on all three groups). Sidak post hoc tests: \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. Cohen's *d* vs. controls. **b** Cocaine user group values corrected for age, verbal IQ, ADHD, abstinence duration, and cumulative cocaine dose (based on cocaine user groups). Sidak post hoc tests: \**p* \< 0.05. Cohen's d lowLevCU vs. highLevCU

Study 2 {#Sec17}
-------

### Demographic characteristics and levamisole analysis {#Sec18}

Again, the three groups did not differ regarding education, sex distribution, smoking status, average price paid for 1 g of cocaine (Table [S3](#MOESM1){ref-type="media"}), and socioeconomic status (Table [S4](#MOESM1){ref-type="media"}). As in Study 1, the two CU groups showed higher BDI and ADHD-SR scores than healthy controls. Moreover, the lowLevCU had a significant lower verbal IQ than the highLevCU group and the controls. Hair toxicology measures between the two CU groups did only differ for the measured levamisole concentration as well as the levamisole-related LCR.

### Thickness measures {#Sec19}

Three-group comparisons revealed significant group effects on cortical thickness for the whole brain ROI (*F*(2,61) = 3.90, *p* \< 0.05), and the MFG (*F*(2,61) = 3.61, *p* \< 0.05; Fig. [3a](#Fig3){ref-type="fig"}, Table [S1](#MOESM1){ref-type="media"}). Both measures showed significant linear trends across groups (*p* \< 0.05) and post hoc pairwise comparisons indicated that cortical thickness was significantly decreased in highLevCU compared to controls. As in Study 1 two additional cocaine-related covariates were added for the two-group ANCOVAs (lowLevCU vs. highLevCU): abstinence duration and cumulative lifetime dose (Fig. [3b](#Fig3){ref-type="fig"}, Table [S2](#MOESM1){ref-type="media"}). A significant group difference was found for the MFG showing a strong effect size (*F*(1,22) = 5.65, *p* \< 0.05, *d* = 0.84). This effect remained significant, when alcohol (pure ethanol in g per week) was considered as an additional covariate (*F*(1,21) = 5.16, *p* \< 0.05, *d* = 0.80) of potential impact on cortical thickness. ANCOVAs for whole brain, IFG, and lOFG---albeit not statistically significant---showed medium effect sizes (*F*(1,22) = 1.52--2.74, *p* = 0.23--0.11, *d* = 0.45--0.56). A small effect was applicable for the SFG (*F*(1,22) = 0.18, *p* = 0.67, *d* = 0.17). By contrast, no effect was found for the pericalcarine gyrus as expected (*F*(1,22) = 0.00, *p* = 0.99, *d* = 0.00). Importantly, MFG thickness was negatively correlated with the log-transformed levamisole hair concentration (*r* = −0.32, *p* \< 0.05, one-tailed; Figure [S5](#MOESM1){ref-type="media"}).Fig. 3Mean cortical thickness (in mm) and standard errors for the whole brain and five regions of interest.**a** All values corrected for age, verbal IQ, and ADHD (based on all three groups). Sidak post hoc tests: \**p* \< 0.05. Cohen's *d* vs. controls. **b** Cocaine user group values corrected for age, verbal IQ, ADHD, abstinence duration, and cumulative cocaine dose (based on cocaine user groups). Sidak post hoc tests: \**p* \< 0.05. Cohen's d lowLevCU vs. highLevCU

Discussion {#Sec20}
==========

The aim of the present studies was to examine whether the worldwide highly prevalent cocaine adulterant levamisole is associated with higher risks for cognitive impairment and structural brain alterations in chronic CU with recent levamisole exposure. We first demonstrated that highLevCU showed significantly worse executive functions (Cohen's *d* = 0.55) compared to individuals with equivalent cocaine use intensity but lower levamisole hair concentrations. Although not significant, similar patterns with approximately medium effect sizes were also found for the global cognition score (*d* = 0.42) and declarative memory performance (*d* = 0.44), but not for attention (*d* = 0.12) and working memory (*d* = 0.04). Notably, compared to stimulant-naive healthy controls, significant cognitive deficits were still present in CU with low levamisole exposure. Based on these initial findings, we subsequently performed a second study employing structural MRI analyses. In line with the results from the cognitive study, we found significantly reduced cortical thickness in the MFG of CU with high levamisole hair concentrations (*d* = 0.84). Moreover, even though not statistically significant-related effects were shown for the whole brain (*d* = 0.56), IFG (*d* = 0.45), and lOFG (*d* = 0.54), while in an occipital control region no levamisole effect was observable (*d* = 0.00).

In sum, these findings confirm our previous proposition^[@CR15],[@CR16]^ that cocaine use is linked with broad cognitive impairments in the present sample. However, also the adulterant levamisole seems to be related to these impairments, most strongly in the executive functions but also in declarative memory and global cognitive functions. Moreover, levamisole-associated reductions of cortical thickness were also found in lateral frontal brain areas, indicating possible neuroanatomical underpinnings of executive function deficits found in highLevCU. In line with an early animal study^[@CR12]^, these results suggest that levamisole is linked to neurotoxic effects also in humans with regular use of levamisole-contaminated cocaine. Importantly, because highLevCU and lowLevCU did not differ in their socioeconomic background and paid comparable prices for their street cocaine, low income is likely not an alternative explanation for the cognitive and cortical alterations found in cocaine users with high levamisole exposure.

Previous studies consistently showed strong deficits of CU in attention and working memory, whereas the heterogeneous concept of executive functions was usually less affected^[@CR15],[@CR38]--[@CR40]^. Here, we also found clear cocaine but no pronounced levamisole effects in the domains of attention and working memory but a significant levamisole effect on executive functions. Thus, one might speculate that at least some of the reported discrepant findings in the newer literature regarding executive function impairments^[@CR41]^ might be explained by differences in recent levamisole exposure. As levamisole was proposed to be metabolized into the amphetamine-like stimulant aminorex and other metabolites^[@CR1],[@CR6],[@CR7]^, and previous reports showed pronounced executive function decrements in chronic amphetamine users^[@CR42],[@CR43]^, the present effect might not be linked to levamisole alone but also to its metabolic products.

The indicated levamisole effect on the executive function domain was mainly driven by low performance in an attentional set-shifting/reversal learning task (IED) and worse recall consistency in a verbal learning task (RAVLT), while the strategy score of a spatial working memory task (SWM) was less affected. This supports the assumption that levamisole might have little effect on working memory processes per se but impacts cognitive flexibility and memory organization. Remarkably, these specific cognitive impairments are well in line with the found structural alterations in the MFG, given that (1) the MFG is prominently involved in attentional set-shifting and reversal learning^[@CR44],[@CR45]^ and (2) patients with focal frontal lesions have difficulties in memory organization such as recall consistency^[@CR18],[@CR19]^. Moreover, frontal lobe atrophy has been shown as the most consistent predictors for recall consistency in patients with multiple sclerosis^[@CR46]^. Finally, age-related changes presumably of the prefrontal cortex (including predominantly the MFG)^[@CR47],[@CR48]^ as well as excitotoxic prefrontal lesions^[@CR49]^ are associated with impairments in set-shifting in monkey models.

To date, the exact neurobiological substrates behind the cocaine-related cognitive alterations are still not fully understood^[@CR50]^. Cocaine is an unspecific monoamine reuptake inhibitor with high affinity for dopamine, serotonin, and norepinephrine transporters (DAT, SERT, and NET)^[@CR51]^. Thus, cognitive deficits most likely depend on adaptions involving regions with high concentrations of monoamine responsive cells such as the prefrontal cortex^[@CR52]^. Also the exact neurobiological effects of levamisole remain unclear. Recent research suggested that levamisole has only minor effects on monoamine transporter^[@CR6]^. Yet, the metabolite aminorex, has a similar affinity to NET and DAT as cocaine, while showing less binding to the SERT^[@CR6]^. However, it is not fully clear if aminorex is able to augment cocaine effects in humans in general, but due to its longer half-life it might at least prolong the stimulant effects of cocaine^[@CR6],[@CR53]^. Interestingly, specific impairments in attentional set-shifting were reported for noradrenergic but not cholinergic deafferentation of the medial prefrontal cortex---the homolog of the primate dorsolateral prefrontal cortex in rats^[@CR54]^. Given that we previously proposed that CU might show neuroplastic adaptations in the noradrenaline system^[@CR55],[@CR56]^ one could speculate that not only cocaine but specifically a cocaine--aminorex combination can disrupt the noradrenaline transmission. Moreover, medically prescribed levamisole intake is supposed to cause multifocal inflammatory leukoencephalopathy^[@CR57],[@CR58]^, a disease associated with white matter lesions. Thus, executive function impairments might be mainly explained by levamisole (or its metabolites) as white matter lesions are associated with cognitive dysfunctions in general^[@CR59]^ and executive function deficits in particular^[@CR60]^. Importantly, executive function deficits are also strongly linked to gray matter alterations in the prefrontal cortex^[@CR61]^. Thus, executive function deficits in highLevCU are likely explained by neuroanatomical alterations of the prefrontal cortex beyond the cortical abnormalities linked to cocaine consumption per se^[@CR42]^.

A limitation of this study is that the objective hair toxicology parameters covered only the last 3 to 6 months. Consequently, the group classification based on the LCR reflected a recent but not necessarily a long-term levamisole exposure. Moreover, we did not apply a neuropsychological test battery in Study 2 at the time of structural imaging and, thus, were not able to directly correlate cognitive performance with cortical thickness scores. Finally, the applied cross-sectional case--control study design makes it impossible to determine the causal relationship between levamisole and neurocognitive and imaging measures.

In conclusion, CU with high levamisole exposure showed significantly worse executive functioning than CU with comparable cocaine use severity but low levamisole contamination. Moreover, high levamisole exposure was associated with lower cortical thickness, primarily for the MFG but also---even though not statistically significant---in additional frontal regions and on a whole brain level. Altogether, our results indicate that exposure to high doses of levamisole during the last months (covered by the hair analyses) goes along with pronounced neurocognitive and cortical alterations in CU, strongly indicating a possible neurotoxic effect of levamisole in humans. Consequently, CU should be better informed about the consequences of levamisole-adulterated cocaine and drug policy makers should consider prevention and harm reduction programs, which lead to a reduction of levamisole contamination of street cocaine such as drug-checking services for users^[@CR62]^.
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